BYSI - Karyopharm Brain Cancer Trial And Other News: The Good Bad And Ugly Of Biopharma
Karyopharm Doses First Patient in Brain Cancer Trial
Karyopharm Therapeutics (KPTI) announced that it has dosed the first patient for its Phase 1/2 clinical trial. The study aims to assess the potential of oral Selinexor in combination with standard of care therapy in treating patients suffering from newly diagnosed or recurrent glioblastoma. This multi-site study is expected to enroll nearly 400 patients in clinical sites spread across the United States, Europe and Israel.
The randomized Phase 1/2 study is scheduled to be conducted in two phases. The Phase 1 study is mainly aimed